

Special Issue

Emerging Topics in Hydrocephalus

Message from the Guest Editor

Hydrocephalus is not a single pathology, but a group of multiple pathologies whose prevalence is unknown. The clinical repercussions are major for the patient in terms of disability, with the development of a clinical triad described by Salomon Hakim and early mortality. Among these pathologies, some have an etiological diagnosis. These are secondary hydrocephalus (post-infectious, posthemorrhagic, etc.). However, the mechanisms of the genesis of hydrocephalus are not perfectly described. Most chronic hydrocephalus remains idiopathic. These cases of idiopathic hydrocephalus are grouped together in a single entity often called “idiopathic normal pressure hydrocephalus”. Their pathophysiology is unknown. Therefore, the mechanisms of action of the treatment are not known, and it does not address the cause. The aim of this Special Issue on hydrocephalus is to describe the different pathophysiological leads to help remove the term idiopathic from our language when we talk about hydrocephalus. This includes studies on the pathophysiology or the development of new and justified classifications of hydrocephalus.

Guest Editor

Dr. Cyrille Capel

Department of Neurosurgery, Hospital University Center of Amiens-Picardie, 80054 Amiens, France

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162899

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).